B. Metzler Seel. Sohn & Co. Ag Bridge Bio Pharma, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10.3 Billion
- Q2 2025
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 36,603 shares of BBIO stock, worth $1.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
36,603
Previous 36,603
-0.0%
Holding current value
$1.8 Million
Previous $1.27 Million
24.9%
% of portfolio
0.02%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding BBIO
# of Institutions
392Shares Held
187MCall Options Held
12.7MPut Options Held
2.28M-
Viking Global Investors LP22.1MShares$1.08 Billion2.55% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY19.3MShares$946 Million30.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$809 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$611 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.17MShares$352 Million0.14% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $7.28B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...